Fidelity Advisor Biotechnology Fund
Actively managed U.S. stock fund
Fidelity Advisor Biotechnology Fund seeks capital appreciation.
The fund invests at least 80% of assets in common stocks of companies principally engaged in biotechnology research, development, manufacture, and distribution, or that benefit significantly from biotechnological advances, using fundamental analysis of financial condition, industry position, and market conditions to select holdings. The fund may also use derivatives to gain exposure to these investments or associated market risk factors. Because security selection depends on the manager's assessment of each company's biotechnology involvement and financial merit, fund performance will diverge from any benchmark.
What you own
| Company | Weight | Value | Shares | Reported price |
|---|---|---|---|---|
ABBVABBVIE INC | 14.83% | $282.21M | 1.3M | $211.32 |
5.52% | $105.07M | 339.5K | $309.49 | |
5.42% | $103.22M | 788.9K | $130.84 | |
INSMINSMED INC | 3.51% | $66.75M | 489.6K | $136.33 |
3.45% | $65.67M | 1.8M | $35.79 | |
3.37% | $64.10M | 730.1K | $87.80 | |
3.33% | $63.41M | 851.8K | $74.45 | |
ASCENDIS PHARMA A/S | 3.24% | $61.75M | 269.2K | $229.38 |
ARGXARGENX SE | 3.17% | $60.35M | 77.2K | $781.72 |
BIIBBIOGEN INC | 2.92% | $55.67M | 294.1K | $189.28 |
Reported price is the fund's own reported value divided by its own reported shares at 2026-04-30 — not a live quote, and not what the fund paid.
All 98 holdings, with the share counts as filed, open with a free account.
What the fund is made of
Percentages are of fund net assets. Rounding, liabilities and short positions can make totals differ from 100%.
| Stocks | 99.22% |
| Cash & short-term | 3.28% |
| Bonds | 0.05% |
By sector
- Health Care
- 86.0%
- International
- 9.2%
- Other
- 2.5%
- Cash
- 2.3%
How it has done
FBTAX share class · total returns with dividends reinvested
Volatility over the last 12 months: 18.10%. Past returns are a record, not a forecast.
May 2026 and Jun 2026 and Jul 2026 have been filed since the trailing figures were struck, so they are not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.
The 5 share classes hold the same portfolio
| Share class | Expense ratio | 1 year | 3 years | 5 years | Worst fall |
|---|---|---|---|---|---|
| 0.96% | +52.17% | -53.11% | -89.89% | -70.17% | |
| 1.71% | +51.03% | +36.14% | -5.30% | -24.86% | |
| 1.21% | +51.77% | -21.76% | -70.45% | -50.11% | |
| 0.71% | +52.58% | +73.95% | +56.20% | -20.46% | |
| 0.58% | +52.76% | +74.64% | +57.18% | -20.41% |
These classes hold the same portfolio, so the 147.07pp spread over 5 years is the cost difference between them — roughly 29.41pp a year — not a difference in what they own.
Fees & fund details
Fidelity Advisor Biotechnology Fund is an actively managed U.S. equity fund.
- Asset class
- Equity
- Region
- United States
- Management
- Actively managed
- Fund type
- Open-end fund
- Features
- Non-diversified
- Expense ratio, by class
- 0.58% – 1.71%· FBTAX 0.96%
- Portfolio turnover
- 51.00% a year · as of 2025 Q3
Turnover is how much of the portfolio was replaced in a year.
Classified from what the fund holds, not from its name · 2026 Q2. The summary is a paraphrase of the prospectus; the objective is verbatim.
What changed this quarter
Positions that entered or left the fund since its previous filing. Positions that were only resized are not listed.
49 new· the largest 8
18 exited· the largest 8
Debt profile
What this fund holds — value-weighted across its bond and securitized long positions · as of 2026-04-30
Share of the fund's debt by how its coupon behaves — the fact that decides whether a rate move reaches this portfolio at all.
| Floating rate | 83.6% |
| Fixed rate | 16.4% |
Share of the fund's debt value in each maturity band, shortest first.
| <1y | 16.4% |
| 10y+ | 83.6% |
Based on what filers reported; a filer that never reported a flag also reads as none.
Understand how this fund fits with the rest.
Explore shared holdings, compare funds and follow their businesses with your connected AI:
- “Where do my funds overlap — FBTAX, QQQ and the fund in my 401(k)?”
- “How do this fund’s ten biggest holdings stack up against each other?”
- “For my target-date fund, what’s the real stock-and-bond mix once you look through it?”